Corteva Agriscience and Belgium-based Globachem have signed a 50/50 joint venture to develop new crop protection solutions, adding a second dedicated partnership vehicle to Corteva's active-ingredient pipeline strategy.

The deal, reported by Indian Chemical News, gives each company an equal equity stake in a venture focused on discovering and commercializing new crop protection products. No financial terms, timeline for first product launches, or target crop and mode-of-action details were disclosed in the announcement.

For Corteva, the joint venture extends an established playbook. The seed and crop protection major has repeatedly used co-development structures to feed its discovery pipeline while sharing the rising cost of bringing new active ingredients to market. Industry benchmarks put the cost of developing a single new crop protection molecule at more than $250 million and roughly a decade from discovery to first sales, a burden that has pushed even the largest input makers toward shared-risk arrangements.

Globachem, headquartered in Belgium, brings synthesis and formulation capabilities that complement Corteva's biological screening and global field-development network. For a mid-sized European chemistry firm, a 50/50 stake alongside one of the world's largest agriscience companies provides direct access to regulatory pathways and distribution reach across North and South America and Asia that it could not build alone.

The joint venture lands in a market where growers face tightening options on several fronts. Regulatory withdrawals of older chemistries in the European Union, resistance pressure in weed and fungal pathogen populations, and generic competition on off-patent actives have squeezed the menu of effective modes of action. New active ingredients that clear regulatory hurdles typically command premium pricing at launch, which flows directly into growers' crop protection budgets — an input line that commonly ranks second only to seed and fertilizer in total cash expenses for row-crop and specialty operations alike.

Corteva's crop protection segment has leaned heavily on its own discovery output, including newer insecticide and fungicide franchises, to sustain margins as glyphosate and other commodity actives face price erosion from Chinese generic supply. A shared-ownership venture shifts part of the development spend off Corteva's balance sheet while preserving access to any resulting products for its global channel.

Neither company specified whether the venture will target synthetic chemistry, biologicals, or both — a distinction that matters for registration timelines, since biological products generally clear regulatory review faster and at lower cost than synthetic actives in most major markets.

The companies also did not say where the joint venture will be headquartered or how research responsibilities will be divided. Further details on governance, staffing, and initial development targets are expected as the agreement moves toward operational launch.